Sapitinib is a quinazoline derivative with the structure 4-amino-7-methoxyquinazoline, where the amino group is replaced by a 3-chloro-2-fluorophenyl group and position 6 of the quinazoline ring is substituted by a {1-[2-(methylamino)-2-oxoethyl]piperidin-4-yl}oxy group. It is a dual tyrosine kinase inhibitor targeting EGFR, HER2, and HER3. Sapitinib functions as an epidermal growth factor receptor antagonist and an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor. It belongs to the classes of quinazolines, piperidines, monofluorobenzenes, monochlorobenzenes, aromatic ethers, secondary amino compounds, and tertiary amino compounds.
